Aubuchon Neil William 4

What Happened
Neil William Aubuchon, Chief Commercial Officer of Viking Therapeutics, purchased 4,475 shares on 2026-03-10 at $33.50 per share, for a total reported cost of $149,913. The Form 4 lists the transaction as a purchase (code P) described as "open market or private purchase." Purchases by executives can be seen as a more informative (bullish) insider action compared with routine sales, though no motive is stated.

Key Details

• Transaction date: 2026-03-10
• Price: $33.50 per share
• Shares acquired: 4,475
• Total reported value: $149,913
• Transaction code: P (purchase); described as "open market or private purchase" in the filing
• Shares owned after transaction: not specified in the provided filing
• Filing date / timeliness: Reported on 2026-03-10 (same day), indicating a timely filing
• No footnotes in the provided summary about 10b5-1 plans, tax withholding, or other special conditions

Context
This was a straightforward share purchase (not an option exercise, award, or gift). For retail investors tracking insider activity, purchases by senior executives can be notable but should be weighed alongside company fundamentals, other insider trades, and market conditions.